دورية أكاديمية
أعرض في EDS

The ApoA-I mimetic peptide 4F attenuates in vitro replication of SARS-CoV-2, associated apoptosis, oxidative stress and inflammation in epithelial cells.

التفاصيل البيبلوغرافية
العنوان: The ApoA-I mimetic peptide 4F attenuates in vitro replication of SARS-CoV-2, associated apoptosis, oxidative stress and inflammation in epithelial cells.
المؤلفون: Kelesidis T; Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA., Madhav S; Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA., Petcherski A; Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA., Cristelle H; Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA., O'Connor E; Molecular Toxicology Interdepartmental Degree Program, University of California Los Angeles, United States., Hultgren NW; Department of Ophthalmology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA., Ritou E; Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA., Williams DS; Department of Ophthalmology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA., Shirihai OS; Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA., Reddy ST; Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.; Molecular Toxicology Interdepartmental Degree Program, University of California Los Angeles, United States.; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
المصدر: Virulence [Virulence] 2021 Dec; Vol. 12 (1), pp. 2214-2227.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101531386 Publication Model: Print Cited Medium: Internet ISSN: 2150-5608 (Electronic) Linking ISSN: 21505594 NLM ISO Abbreviation: Virulence Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin, Tex. : Landes Bioscience
مواضيع طبية MeSH: Antiviral Agents/*pharmacology , Peptides/*pharmacology , SARS-CoV-2/*drug effects , Virus Replication/*drug effects, Animals ; Antioxidants/pharmacology ; Apoptosis/drug effects ; Basigin/metabolism ; Cytokines/metabolism ; Epithelial Cells ; Heparan Sulfate Proteoglycans/metabolism ; Humans ; Inflammation ; Interferons/metabolism ; Oxidative Stress/drug effects ; SARS-CoV-2/physiology ; Spike Glycoprotein, Coronavirus/metabolism ; Virus Attachment/drug effects ; Virus Internalization/drug effects
مستخلص: An oral antiviral against SARS-CoV-2 that also attenuates inflammatory instigators of severe COVID-19 is not available to date. Herein, we show that the apoA-I mimetic peptide 4 F inhibits Spike mediated viral entry and has antiviral activity against SARS-CoV-2 in human lung epithelial Calu3 and Vero-E6 cells. In SARS-CoV-2 infected Calu3 cells, 4 F upregulated inducers of the interferon pathway such as MX-1 and Heme oxygenase 1 (HO-1) and downregulated mitochondrial reactive oxygen species (mito-ROS) and CD147, a host protein that mediates viral entry. 4 F also reduced associated cellular apoptosis and secretion of IL-6 in both SARS-CoV-2 infected Vero-E6 and Calu3 cells. Thus, 4 F attenuates in vitro SARS-CoV-2 replication, associated apoptosis in epithelial cells and secretion of IL-6, a major cytokine related to COVID-19 morbidity. Given established safety of 4 F in humans, clinical studies are warranted to establish 4 F as therapy for COVID-19.
References: Free Radic Biol Med. 1996;21(5):641-9. (PMID: 8891667)
Nat Rev Drug Discov. 2017 Dec 28;17(1):78. (PMID: 29282366)
Biochem Biophys Res Commun. 2004 Jul 9;319(4):1228-34. (PMID: 15194498)
Circulation. 2014 Aug 26;130(9):776-85. (PMID: 24963038)
BMB Rep. 2008 Aug 31;41(8):560-7. (PMID: 18755070)
Front Pharmacol. 2020 Jul 29;11:1169. (PMID: 32848776)
J Lipid Res. 2011 Feb;52(2):361-73. (PMID: 21068008)
Arch Med Res. 2020 Apr;51(3):282-286. (PMID: 32229155)
EMBO Mol Med. 2019 Sep;11(9):e10061. (PMID: 31468711)
Eur Respir J. 2020 Sep 24;56(3):. (PMID: 32631841)
Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2631-9. (PMID: 22982462)
Cell Discov. 2020 Nov 4;6(1):80. (PMID: 33298900)
Nat Clin Pract Cardiovasc Med. 2006 Oct;3(10):540-7. (PMID: 16990839)
Cell Stress Chaperones. 2020 Sep;25(5):707-710. (PMID: 32500379)
Nature. 2006 Dec 14;444(7121):860-7. (PMID: 17167474)
Circulation. 2005 Jun 14;111(23):3126-34. (PMID: 15939814)
Cancer Metastasis Rev. 2020 Jun;39(2):337-340. (PMID: 32385712)
Mol Pharmacol. 2012 Aug;82(2):246-54. (PMID: 22570368)
Treat Respir Med. 2005;4(2):107-16. (PMID: 15813662)
Cardiovasc Res. 2004 Feb 15;61(3):372-85. (PMID: 14962470)
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):258-259. (PMID: 32347925)
Drug Metab Lett. 2010 Aug;4(3):139-48. (PMID: 20642447)
ACS Chem Neurosci. 2020 Dec 16;11(24):4017-4020. (PMID: 33275404)
Cell Res. 2020 Mar;30(3):269-271. (PMID: 32020029)
J Lipids. 2011;2011:730209. (PMID: 21490811)
J Thromb Thrombolysis. 2020 Oct;50(3):512-524. (PMID: 32880795)
Pulm Circ. 2016 Sep;6(3):261-73. (PMID: 27683603)
Virology. 2017 Mar;503:1-5. (PMID: 28068513)
Oxid Med Cell Longev. 2016;2016:4350965. (PMID: 26998193)
Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):164-8. (PMID: 19608977)
Virology. 1990 May;176(1):48-57. (PMID: 2158697)
Matrix Biol. 2017 Jan;57-58:285-298. (PMID: 27613501)
J Clin Invest. 2019 Jun 11;129(9):3670-3685. (PMID: 31184596)
Cell Signal. 2006 Dec;18(12):2238-51. (PMID: 16806820)
Nature. 2006 Dec 21;444(7122):1022-3. (PMID: 17183309)
J Lipid Res. 2013 Apr;54(4):995-1010. (PMID: 23378594)
Cell. 2020 Nov 12;183(4):1043-1057.e15. (PMID: 32970989)
Am J Physiol Lung Cell Mol Physiol. 2002 Jun;282(6):L1324-9. (PMID: 12003789)
Sci Rep. 2018 Jun 13;8(1):9032. (PMID: 29899427)
N Engl J Med. 2020 Nov 5;383(19):1827-1837. (PMID: 32459919)
Int J Cancer. 2012 Mar 1;130(5):1071-81. (PMID: 21425255)
Vaccine. 2003 May 1;21(16):1796-800. (PMID: 12686097)
Infect Immun. 2006 Dec;74(12):6581-9. (PMID: 17015453)
Adv Virus Res. 2016;96:165-192. (PMID: 27712623)
J Virol. 2012 Dec;86(24):13445-55. (PMID: 23015724)
Mol Cell Biol. 2005 Jun;25(12):4853-62. (PMID: 15923604)
Nature. 2020 Sep;585(7825):339-341. (PMID: 32929257)
Virology. 1999 Dec 5;265(1):96-109. (PMID: 10603321)
J Mol Cell Cardiol. 2017 Apr;105:77-88. (PMID: 28274624)
Int Immunopharmacol. 2011 Dec;11(12):2112-7. (PMID: 21945667)
J Virol. 2009 Oct;83(20):10605-15. (PMID: 19706715)
J Cell Sci. 2001 Apr;114(Pt 7):1397-408. (PMID: 11257005)
J Biol Chem. 2012 Apr 27;287(18):14880-95. (PMID: 22389508)
J Trauma Acute Care Surg. 2012 Jun;72(6):1576-83. (PMID: 22695425)
Pharmacol Res Perspect. 2015 Aug;3(4):e00154. (PMID: 26171234)
J Clin Med. 2020 Jun 18;9(6):. (PMID: 32570882)
J Virol. 2015 Aug;89(16):8318-33. (PMID: 26041291)
J Lipid Res. 2008 Jun;49(6):1344-52. (PMID: 18323573)
Emerg Microbes Infect. 2021 Dec;10(1):317-330. (PMID: 33560940)
Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264)
Int J Mol Med. 2009 Jan;23(1):41-8. (PMID: 19082505)
Front Immunol. 2020 Sep 29;11:574508. (PMID: 33133090)
Lancet Respir Med. 2020 Jun;8(6):e46-e47. (PMID: 32353251)
J Control Release. 2021 Jan 10;329:758-761. (PMID: 33038449)
J Lipid Res. 2008 Nov;49(11):2302-11. (PMID: 18621920)
Clin Transl Sci. 2017 Nov;10(6):455-469. (PMID: 28795506)
iScience. 2020 Oct 23;23(10):101585. (PMID: 32989429)
J Cardiovasc Transl Res. 2015 Feb;8(1):59-66. (PMID: 25604960)
PLoS One. 2017 Apr 28;12(4):e0176124. (PMID: 28453517)
Circulation. 2004 Nov 16;110(20):3252-8. (PMID: 15533864)
Virology. 2019 Feb;528:80-88. (PMID: 30580124)
J Virol. 2018 Jan 30;92(4):. (PMID: 29167338)
Sci Rep. 2017 Sep 12;7(1):11367. (PMID: 28900160)
Circulation. 2002 Aug 27;106(9):1127-32. (PMID: 12196340)
Mol Neurobiol. 2012 Aug;46(1):85-95. (PMID: 22476944)
N Engl J Med. 2020 Nov 5;383(19):1813-1826. (PMID: 32445440)
Cell Mol Immunol. 2020 Aug;17(8):881-883. (PMID: 32555321)
Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8091-6. (PMID: 18523003)
J Biol Chem. 2004 Mar 19;279(12):11112-8. (PMID: 14707126)
Adv Exp Med Biol. 2017;982:407-429. (PMID: 28551800)
Curr Atheroscler Rep. 2009 Jan;11(1):52-7. (PMID: 19080728)
Viruses. 2020 May 06;12(5):. (PMID: 32384820)
Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1426-32. (PMID: 15845909)
J Virol. 2021 Apr 12;95(9):. (PMID: 33608407)
Genome Biol. 2006;7(10):R100. (PMID: 17076895)
J Pharm Sci. 2009 Feb;98(2):606-19. (PMID: 18563833)
معلومات مُعتمدة: R01 AG059502 United States AG NIA NIH HHS; R21 NR010361 United States NR NINR NIH HHS; K08 AI108272 United States AI NIAID NIH HHS; R25 GM055052 United States GM NIGMS NIH HHS; P30 AI028697 United States AI NIAID NIH HHS; R03 AG059462 United States AG NIA NIH HHS; R01 HL071776 United States HL NHLBI NIH HHS; R01 AG025501 United States AG NIA NIH HHS; R21 AI036178 United States AI NIAID NIH HHS; R43 AG059501 United States AG NIA NIH HHS
فهرسة مساهمة: Keywords: 4F; ApoA-I mimetic peptides; COVID-19; SARS-CoV-2; antioxidants; antivirals; apoptosis; inflammation; therapeutics
المشرفين على المادة: 0 (Antioxidants)
0 (Antiviral Agents)
0 (Cytokines)
0 (Heparan Sulfate Proteoglycans)
0 (Peptides)
0 (Spike Glycoprotein, Coronavirus)
0 (apolipoprotein A-I mimetic peptide 4F)
0 (spike protein, SARS-CoV-2)
136894-56-9 (Basigin)
9008-11-1 (Interferons)
تواريخ الأحداث: Date Created: 20210908 Date Completed: 20210915 Latest Revision: 20231107
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC8437485
DOI: 10.1080/21505594.2021.1964329
PMID: 34494942
قاعدة البيانات: MEDLINE
الوصف
تدمد:2150-5608
DOI:10.1080/21505594.2021.1964329